NEW YORK (GenomeWeb News) —Hologic reported after the close of the market on Monday that fiscal first-quarter revenues declined 3 percent year over year, although its molecular diagnostic product sales helped mitigate this decline.

For the three months ended Dec. 28, 2013, Hologic's revenues totaled $612.4 million compared to $631.4 million a year ago, but besting the consensus Wall Street estimate of $609.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.